United Therapeutics (NASDAQ:UTHR) CEO Sells $5,051,530.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction on Friday, July 24th. The stock was sold at an average price of $531.74, for a total transaction of $5,051,530.00. Following the completion of the sale, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $172,519,320.82. This represents a 2.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

United Therapeutics Stock Down 0.3%

UTHR traded down $1.44 during midday trading on Tuesday, hitting $526.50. 62,992 shares of the company were exchanged, compared to its average volume of 480,858. The firm’s 50 day moving average price is $547.10 and its 200-day moving average price is $531.86. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35. The firm has a market capitalization of $22.35 billion, a P/E ratio of 19.47, a P/E/G ratio of 1.77 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics’s revenue was down 1.6% compared to the same quarter last year. During the same quarter last year, the business earned $6.63 earnings per share. On average, sell-side analysts predict that United Therapeutics Corporation will post 26.65 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on UTHR. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. JPMorgan Chase & Co. boosted their price target on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Royal Bank Of Canada raised their price objective on shares of United Therapeutics from $701.00 to $704.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. HC Wainwright lifted their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Finally, Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a report on Thursday, May 7th. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $648.33.

Hedge Funds Weigh In On United Therapeutics

A number of institutional investors have recently modified their holdings of the company. Wellington Management Group LLP grew its position in United Therapeutics by 74.5% in the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after purchasing an additional 1,042,711 shares during the period. Norges Bank acquired a new position in United Therapeutics during the fourth quarter worth $293,418,000. Avoro Capital Advisors LLC raised its holdings in United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after buying an additional 383,838 shares during the last quarter. Janus Henderson Group PLC lifted its stake in shares of United Therapeutics by 75.1% in the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock valued at $387,801,000 after buying an additional 341,383 shares in the last quarter. Finally, Baillie Gifford & Co. acquired a new position in shares of United Therapeutics during the fourth quarter valued at about $157,390,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.